STOCK TITAN

iBio, Inc. - $IBIO STOCK NEWS

Welcome to our dedicated page for iBio news (Ticker: $IBIO), a resource for investors and traders seeking the latest updates and insights on iBio stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect iBio's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of iBio's position in the market.

Rhea-AI Summary
iBio files annual report with the SEC, reporting $nil in revenues for FY 2023 compared to $1.9 million in FY 2022. Operating expenses decrease by 7% to $29.3 million. Consolidated net loss increases by $14.6 million to $65.0 million. iBio holds $4.3 million in cash and cash equivalents and $3.3 million in restricted cash. The audited financial statements contain an audit opinion regarding the Company's ability to continue as a going concern. The maturity date of the Credit Agreement is extended to December 31, 2023, providing time to close the sale of the CDMO Facility. No assurance of closing conditions being satisfied. The divestiture of iBio's manufacturing business in Texas will extend cash runway for AI drug discovery platform and immunotherapy pipeline.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
iBio extends maturity date of credit agreement to December 31, 2023, allowing time to close pending sale of CDMO facility. Sale of facility will complete divestiture of contract development and manufacturing business. Positive for stock price.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.06%
Tags
none
-
Rhea-AI Summary
iBio announces positive pre-clinical data for three immuno-oncology candidates, including a 43% reduction in tumor growth with anti-EGFRvIII antibody and a 36% reduction in tumor size with TROP-2 x CD3 antibody.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.67%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.35%
Tags
management
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.74%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.33%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.75%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-18.12%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.95%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
97.33%
Tags
none
iBio, Inc.

NYSE:IBIO

IBIO Rankings

IBIO Stock Data

17.14M
1.25M
0.18%
26.9%
4.64%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
NEW YORK

About IBIO

ibio is a contract development and manufacturing organization equipped to take clients from the early stages of product selection through regulatory approval and commercial product launch. ibio’s technology platform and facility capabilities are applicable to the development of biotherapeutics, vaccines, diagnostic products, and certain types of medical devices – and often provide significant time and value advantages over traditional approaches. ibio’s lab to launch capabilities assure the most rapid manufacturing support to reach the clinic. ibio’s team is comprised of knowledgeable protein scientists, microbiologists and manufacturing and regulatory experts, all of whom add significant expertise and value throughout the entire process. the same team and facility that produces preclinical and clinical material will be the same team producing your product for market launch; contributing to the seamless scale-up process the ibio technology platform creates.